Effects of transplanted circulating endothelial progenitor cells and platelet microparticles in atherosclerosis
Adriana Georgescu1,2, Nicoleta Alexandru1,2, Eugen Andrei1
1Institute of Cellular Biology and Pathology 'Nicolae Simionescu' of Romanian Academy, Bucharest, Romania.
Insights
Endothelial progenitor cell therapy effectively suppressed atherosclerosis development in a hamster model. This approach reduced lipid accumulation and improved vascular function, offering a promising therapeutic strategy for atherosclerosis.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Cell Therapy
Background:
- Atherosclerosis is an inflammatory disease driven by factors like hyperlipidemia and hypertension, impacting endothelial cells.
- Circulating endothelial progenitor cells (EPCs) and microparticles are key indicators for atherosclerosis outcomes.
- The therapeutic potential of EPCs and microparticles in atherosclerosis remains underexplored.
Purpose of the Study:
- To investigate the protective role of EPC-based cell therapy in atherosclerosis.
- To evaluate the dual behavior of circulating platelet microparticles (PMPs) in atherosclerosis development.
- To assess these effects in a hypertensive-hypercholesterolemic hamster model.
Main Methods:
- Administered intravenous inoculations of EPCs or a combination of EPCs and PMPs to hamsters over several months.
- Utilized a diet-induced atherosclerosis model in hypertensive-hypercholesterolemic hamsters.
- Monitored plasmatic parameters, lipid/macrophage/microparticle accumulation, arterial function, and inflammatory markers.
Main Results:
- EPC treatment normalized plasmatic parameters, reduced lipid/macrophage/microparticle accumulation in the liver and arterial wall, and improved arterial function.
- EPCs were recruited and incorporated into the liver and arterial wall, reducing pro-inflammatory molecule expression.
- PMP transplantation exacerbated atherosclerosis, while co-inoculation with EPCs partially reverted these negative effects.
Conclusions:
- EPC-based therapy effectively suppresses atherosclerosis development, reduces hepatic lipid and macrophage accumulation, and alleviates dyslipidemia and hypertension in a relevant animal model.
- Increasing circulating EPC numbers represents a promising therapeutic strategy for atherosclerosis.
- Understanding the dual role of PMPs is crucial for developing effective atherosclerosis treatments.
Background Information:
Atherosclerosis is an inflammatory disease, in which risk factors such as hyperlipidemia and hypertension affect the arterial endothelium, resulting in dysfunction, cell damage or both. The number of circulating endothelial progenitor cells and microparticles provides invaluable outcome prediction for atherosclerosis disease. However, evidence for the therapeutic potential of endothelial progenitor cells and microparticles in atherosclerosis development is limited. Our study was designed to investigate the possible protective role of a cell therapy-based approach, using endothelial progenitor cells and the dual behaviour of circulating platelet microparticles, on atherosclerosis development in hypertensive-hypercholesterolemic hamster model. Consequently, control hamsters received four intravenous inoculations of: (1) 1×10(5) endothelial progenitor cells of healthy origins in one dose per month, during four months of diet-induced atherosclerosis, and after hypertensive-hypercholesterolemic diet for further four months; (2) in a second set of experiments, 1×10(5) endothelial progenitor cells of healthy origins or/and 1×10(5) platelet microparticles of atherosclerotic origins were inoculated every other month during hypertensive-hypercholesterolemic diet.
Results:
Endothelial progenitor cell treatment had the following effects: (1) re-established plasmatic parameters: cholesterol and triglyceride concentrations, blood pressure, heart rate, cytokine and chemokine profiles, platelet microparticle pro-thrombotic activity and endothelial progenitor cell paracrine activity reflected by cytokine/chemokine detection; (2) reduced lipid, macrophage and microparticle accumulation in liver; (3) reduced atherosclerosis development, revealed by decreased lipid, macrophage and microparticle content of arterial wall; (4) induced the recruitment and incorporation of endothelial progenitor cells into liver and arterial wall; (5) improved arterial dysfunction by increasing contraction and relaxation; (6) reduced the protein expression of specific pro-inflammatory molecules in liver and arterial wall. Platelet microparticle transplantation aggravated the above-mentioned biomarkers and atherosclerosis process, which were partially reverted with co-inoculation of platelet microparticles and endothelial progenitor cells.
Conclusions:
With this study, we demonstrate in a hypertensive-hypercholesterolemic hamster model, that the endothelial progenitor cell-based therapy suppresses the development of atherosclerosis and reduces hepatic lipid and macrophage accumulation with the consequent alleviation of dyslipidaemia and hypertension.
Significance:
Our results support the notion that increasing the number of circulating endothelial progenitor cells by different ways could be a promising therapeutic tool for atherosclerosis.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
09:26Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
Published on: February 20, 2015
Related Concept Videos
Coronary Artery Disease II: Pathophysiology
Atherosclerosis I: Introduction
Peripheral Artery Disease I: Introduction
